Skip to content

Moderna

US · MRNA #406 by market cap Listed 2018
195.00 -4.33 -2.17%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Mixed / stable
  • The number of reporting institutions decreased by 2 in the most recent period (2026/Q4).
  • Total institutional ownership (as a % of shares) was little changed.

Ownership vs. money flow

Diverging

Institutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
78.28% -0.09pp
Institutions
1,222 -2
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund64.29%
Individual/Insider6.57%
Hedge Fund4.09%
Private Company3.18%
Public Company2.80%
VC/PE Fund1.74%
Government Pension Fund0.82%
Sovereign Wealth Fund0.75%
Family Office/Trust0.32%
Other15.44%

Top holders as of 2026-09-30

FMR 14.44% · 58.45M sh
BlackRock 6.87% · 27.80M sh
Vanguard Capital Management, LLC 6.43% · 26.00M sh
Capital Research 5.60% · 22.64M sh
Stéphane Bancel 5.49% · 22.22M sh
Other 61.92%
Vanguard Portfolio Management, LLC 3.90% · 15.78M sh
State Street Global Advisors 3.82% · 15.47M sh
Baillie Gifford 2.83% · 11.44M sh
Geode Capital Management, LLC 2.53% · 10.24M sh
Theleme Partners LLP 2.02% · 8.06M sh
T. Rowe Price Group, Inc. 1.88% · 7.62M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 22 buys · 27 sells

NameRoleStake
Stéphane Bancel Chief Executive Officer 5.49%
Noubar Afeyan Co-Founder, Independent Non Executive Chairman & Member of Technology Advisory Board 0.55%
Stephen Hoge President 0.36%
Paul Sagan Former Independent Non-Executive Director 0.08%
Juan Andres Chief Operating Officer 0.03%
Shannon Klinger Chief Legal Officer 0.02%
James Mock Chief Financial Officer 0.01%
Francois Nader Independent Non-Executive Director 0.01%
Elizabeth Nabel Independent Director 0.00%
Sandra Horning Independent Director 0.00%
Shah Abbas Hussain Director 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-04 Juan Andres Chief Operating Officer Other Derivative Acquisition +7,898 $241.46
2026-11-04 Juan Andres Chief Operating Officer Other Derivative Acquisition +16,955 --
2026-10-14 Stephen Hoge President Derivative Exercise and Sale -78,369 $12.21–220.72
2026-10-14 Stephen Hoge President Derivative Exercise and Retained +74,536 $12.21
2026-10-14 Stephen Hoge President Intent to Sell (Form 144) -39,145 $220.72
2026-10-13 Stephen Hoge President Intent to Sell (Form 144) -39,224 $213.48
2026-10-04 Juan Andres Chief Operating Officer Initial Statement of Beneficial 0 --
2026-10-04 James Mock Chief Financial Officer Derivative Exercise and Sale -704 $190.01
2026-10-04 James Mock Chief Financial Officer Derivative Exercise and Retained +750 --
2026-09-14 Stephen Hoge President Derivative Exercise and Sale -80,575 $12.21–146.07
2026-09-14 Stephen Hoge President Derivative Exercise and Retained +72,330 $12.21
2026-09-14 Stephen Hoge President Intent to Sell (Form 144) -40,281 $146.07
2026-09-13 Stephen Hoge President Intent to Sell (Form 144) -40,294 $144.13
2026-09-09 James Mock Chief Financial Officer Automatic Disposition -15,000 $134.49
2026-09-09 James Mock Chief Financial Officer Derivative Exercise and Sale -19,836 $30.96–134.49
2026-09-03 Shannon Klinger Chief Legal Officer Derivative Exercise and Sale -5,704 $148.87
2026-09-03 Shannon Klinger Chief Legal Officer Derivative Exercise and Retained +6,093 --
2026-09-03 James Mock Chief Financial Officer Derivative Exercise and Sale -5,704 $148.87
2026-09-03 James Mock Chief Financial Officer Derivative Exercise and Retained +6,093 --
2026-08-31 Shannon Klinger Chief Legal Officer Sale to Issuer -1,048 $140.34

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.

Moderna discussion 0 comments

Add a comment